



## REVIEW

# The meaning of sputum eosinophil in childhood asthma and its current application

## *La signification de l'expectoration d'éosinophile dans l'asthme infantile et son application actuelle*

T. Ho-Ly-Minh<sup>1</sup>, S. Bui-Binh-Bao<sup>1</sup>, S. Duong-Quy<sup>2,3</sup>

<sup>1</sup>: Department of Pediatric. Hue University of Medicine. Hue - Vietnam

<sup>2</sup>: Lam Dong Medical College. Dalat - Vietnam

<sup>3</sup>: Penn State Medical College. Hershey Medical Center. USA

### ABSTRACT

Eosinophil infiltration plays an important role in the pathogenesis of asthma. It is important for a health care provider to determine which subtype of asthma a person might have, because there are now new therapies that target specific subgroups of asthma, like eosinophilic asthma.

The term “*eosinophilic asthma*” describes a subphenotype of asthma that is characterised by elevated levels of eosinophils in bronchial biopsies or sputum despite chronic and correct use of adequate doses of inhaled corticosteroids (ICS). Traditionally, airway biopsies or bronchoalveolar lavage through bronchoscopy is considered as the gold standard for assessing airway inflammation but the invasiveness of these methods limits their use in clinical practice.

Biomarkers for type 2 (TH2) inflammation, including FENO (fractional exhaled nitric oxide) levels and blood/sputum eosinophilia and serum periostin levels, have helped to identify a type 2 molecular phenotype of asthma. Sputum induction and differential cell count, unfortunately, are available only in a limited number of specialized centers. Although numerous studies in adults have shown induced sputum analysis to be a useful and safe tool in the evaluation of asthma, very few studies have evaluated this tool in children.

In Vietnam, hardly no clinical setting has applied sputum eosinophil in monitoring asthma because of strict requirements of the method. Thus, here is really avoid space for Vietnamese researchers, especially pulmonologists, that they need to compensate it in the future.

**KEYWORDS:** Asthma, eosinophilic asthma, inhaled corticosteroids, induced sputum.

### RÉSUMÉ

L'infiltration des éosinophiles joue un rôle important dans la pathogenèse de l'asthme. Il est important pour le personnel médical de déterminer quel sous-type d'asthme une personne pourrait avoir, car il existe maintenant de nouvelles thérapies ciblant des sous-groupes spécifiques d'asthme, comme l'asthme à éosinophile.

Le terme «asthme éosinophilique» décrit un sous-phénotype de l'asthme qui est caractérisé par des taux élevés d'éosinophiles dans les biopsies bronchiques ou les expectorations malgré l'utilisation chronique et correcte de doses adéquates de corticostéroïdes inhalés (CSI). Traditionnellement, la biopsie des voies aériennes ou le lavage broncho-alvéolaire par bronchoscopie sont considérés comme les critères d'or pour évaluer l'inflammation des voies aériennes, mais le caractère envahissant de ces méthodes limitent leur utilisation dans la pratique clinique.

Les biomarqueurs de l'inflammation de type 2 (TH2), y compris la concentration de FENO (fraction de monoxyde d'azote expiré) et les taux d'éosinophilie et de périostine dans le sang et les expectorations, ont aidé à identifier un phénotype moléculaire de type 2 de l'asthme. L'induction des expectorations et le nombre de cellules différentielles ne sont malheureusement disponibles que dans un nombre limité de centres spécialisés. Bien que de nombreuses études chez l'adulte aient montré que l'analyse des expectorations induites est un outil utile et sûr dans l'évaluation de l'asthme, très peu d'études ont évalué cette technique chez les enfants.

Au Vietnam, il n'y a aucun contexte clinique appliquant difficilement l'expectoration éosinophile dans la surveillance de l'asthme en raison des exigences très strictes de cette méthode. Ainsi, les chercheurs vietnamiens, en particulier les pneumologues, ont vraiment besoin d'en compenser dans l'avenir.

**MOTS CLÉS:** Asthme, asthme éosinophilique, corticostéroïdes inhalées, expectoration induite.

*Corresponding author:* Dr. HO-LY-MINH Tien. Department of Pediatric. Hue University of Medicine. Hue - Vietnam.  
Email: holyminhvien2007@yahoo.com

## INTRODUCTION

Asthma treatments are predominantly nonspecific anti-inflammatory drugs (corticosteroids) and bronchodilators (beta2-agonists), which works in most patients. However, even responses to these treatments vary. Otherwise, while forced expiratory volume during the first second (FEV<sub>1</sub>) is used to measure lung function in asthma, inflammation and remodeling can persist even when FEV<sub>1</sub> has returned to normal. Although multiple factors can contribute to poor responses, underlying pathobiological differences are increasingly recognized to play a role. Specific subgroups of asthma patients could be identified, either on the basis of clinical characteristics (with or without frequent exacerbations), age of asthma onset (childhood onset *versus* adult onset), lung function abnormalities (with or without persistent airflow limitation), trigger factors (allergic, nonallergic or aspirin induced) or type of airway inflammation (eosinophilic *versus* noneosinophilic) [1]. Although various phenotype clusters and endotypes have been proposed, there is still much unknown about gene expression, the effect of environment and comorbidities, the stability of phenotypes over time, and the appropriate use of biomarkers.

## ROLE OF SPUTUM EOSINOPHIL IN CHILDHOOD ASTHMA

Eosinophil infiltration plays an important role in the pathogenesis of asthma. It is important for a health care provider to determine which subtype of asthma a person might have, because there are now new therapies that target specific subgroups of asthma, like eosinophilic asthma. The term "*eosinophilic asthma*" describes a subphenotype of asthma that is characterised by elevated levels of eosinophils in bronchial biopsies or sputum despite chronic and correct use of adequate doses of ICS [1]. Sputum eosinophil percentage identifies patients who have eosinophilic or non-eosinophilic asthma phenotype. Cai *et al.* demonstrated that the maximum percentage of eosinophils in the sputum of normal children is 2.5% [2]. It has been shown that sputum eosinophil numbers are higher in atopic as compared to non-atopic childhood asthma [3]. Asthma management guided by eosinophils in sputum rather than according to asthma control measures results in better outcomes [4].

Diagnosing eosinophilic asthma is important. Many studies demonstrated that airway inflammation, especially eosinophilic inflammation, was associated with asthma severity and reduced pulmonary function in children [5-7]. A study of Simpson *et al* [8] that examined eosinophil and neutrophil

percentage sin induced sputum found four inflammatory subtypes: eosinophilic, neutrophilic, mixed granulocytic, and pauci-granulocytic asthma. There has been long standing evidence that patients with eosinophilic asthma have greater responsiveness to steroids compared with those with neutrophilic asthma [9]. Patients with symptoms and evidence of eosinophilic inflammation are likely to respond to ICS, but in the absence of airway eosinophilia, patients should not be treated with ever increasing doses of corticosteroids.

Those with persistent eosinophilia despite being treated with inhaled or oral corticosteroids are at risk of severe exacerbations and airway remodeling and should therefore be monitored more intensively. Several studies have shown that late-onset eosinophilic asthma is associated with more severe disease than non-eosinophilic asthma. High levels of eosinophils in sputum and bronchial biopsies are associated with poor asthma control, more severe asthma and fatal or near-fatal asthma attacks. In a biopsy study of patients with severe asthma, it appeared that the patients who had eosinophilic inflammation despite systemic corticosteroids had an almost 20 times higher odds of being intubated than those without eosinophilic inflammation. In patients who died from asthma, significantly more eosinophils were found in large and small airways, as compared to biopsies from patients with milder exacerbations [1]. Significant heterogeneity in response to therapy exists even within eosinophilic asthma, as exemplified by patients with eosinophilic asthma that is refractory to medical therapy with steroids [10]. Some patients might respond better to one biologic agent than another or not at all. The reasons for these differential responses are unknown [11]. The current hope is that a better understanding of asthma heterogeneity will allow us to select treatments based on the greatest likelihood of therapeutic response, thereby improving asthma control and quality of life for patients [12].

## HOW TO DIAGNOSE EOSINOPHILIC ASTHMA IN CHILDREN

Traditionally, airway biopsies or bronchoalveolar lavage through bronchoscopy is considered as the gold standard for assessing airway inflammation [13] but the invasiveness of these methods limits their use in clinical practice. Therefore, there has been great interest in methods to assess airway inflammation noninvasively and in a convenient and inexpensive way. Induced sputum analysis is a less invasive alternative to bronchoscopy for assessing airway inflammation in children with mild to moderate asthma. The most common and best validated method to diagnose eosinophilic asthma is

detection of eosinophils in induced sputum [14]. Sputum induction was developed in the late 1980s for diagnosis of *P. jirovecii* pneumonia among immunocompromised adults. Induced sputum is a relatively safe, semi-invasive method which can be generally performed well by school-age children. Among asthmatic children >6 years undergoing sputum induction, 76-100% of patients successfully complete the procedure [15]. Evaluation of sputum allows direct evaluation of bronchial inflammation, brings data on early inflammatory response and allows the identification of different phenotypes of asthma. A phenotype involves the complex interaction of many genetic and environmental factors in conjunction with observable characteristics, such as lung function (for asthma) or specific IgE responsiveness to particular allergens. The eosinophilic asthma phenotype appears to be more common in patients with adult-onset asthma than in those with childhood-onset asthma [1].

#### RELATIONSHIPS OF SPUTUM EOSINOPHIL WITH OTHER BIOMARKERS

Biomarkers for type 2 (TH2) inflammation, including FENO (fractional exhaled nitric oxide) levels and blood/sputum eosinophilia and serum periostin levels, have helped identify a type 2 molecular phenotype of asthma. Patients with eosinophilic asthma should ideally be diagnosed by analysing sputum samples. However, sputum induction is not easy to perform in routine clinical practice and requires access to specific laboratories with trained personnel. Therefore, the use of several alternatives to sputum cell counts, including peripheral blood eosinophils, FENO and serum IgE have recently been evaluated in a systematic review. The results show that overall, blood eosinophils, FENO and IgE have only moderate accuracy to distinguish between patients with and without airway eosinophilia [16]. Study of Hastie *et al* found that FENO levels, IgE levels, and blood eosinophil are poor surrogates for accurately predicting sputum eosinophil percentages [17].

Because sputum eosinophil measurement is not generally available, subsequent studies identified “eosinophilic (type2-high) asthma” in relation to blood eosinophil counts. The use of blood eosinophils to identify sputum eosinophilia is still debated because of the relatively high false-negative and false-positive rates [17]. Study of Palomino *et al* suggested that eosinophils in sputum were the most accurate marker of inflammation of the airways, since eosinophils in peripheral blood can be elevated in other conditions such as rhinitis and eczema and are not related with asthma severity [2]. Merely for the diagnosis of “eosinophilic asthma”, one single

measurement of blood eosinophils does not seem to be of great value. The most important role for blood eosinophils is probably its role in identifying patients who are likely to respond to treatment with the new biological agents against type 2 inflammation [18]. However, blood eosinophils seem to be less suitable to monitor treatment response.

#### CURRENT APPLICATION OF SPUTUM EOSINOPHIL

Although it had been reported for years that corticosteroid responses were dependent on lung eosinophils, asthma phenotype was rarely considered when planning therapy. With the continued presence of severe refractory asthma and the emergence of new biologics, there is a resurgence of interest in identifying treatment-responsive phenotypes. Sputum induction and differential cell count, unfortunately, are available only in a limited number of specialized centers. Although numerous studies in adults have shown induced sputum analysis to be a useful and safe tool in the evaluation of asthma, very few studies have evaluated this tool in children. Despite the relative safety and tolerability of sputum induction in children, it has several potential limitations. First, the procedure requires a substantial amount of time to perform and process (average of 3 hours). Second, significant technical support and expertise are required to process, stain, and interpret the samples. This also means that the results are not readily available. Third, some children are not able to provide technically adequate or acceptable samples. Finally, few patients can develop bronchospasm despite pretreatment [5].

There are no consensus guidelines from the large respiratory societies that advocate for use of biomarkers in guiding asthma management [19]. NHLBI—National Asthma Education Prevention Program states that “biomarkers, such as sputum eosinophils and FENO, are increasingly used in clinical research and will require further evaluation in adults and children before they can be recommended as a clinical tool for routine asthma management” [20]. Also, Global Strategy for Asthma Management and Prevention (GINA) does not make a recommendation about measurement of sputum eosinophilia or FENO [21]. On the other hand, the British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network (SIGN) guidelines recommend clinicians “consider monitoring induced sputum eosinophil counts to guide steroid treatment” in patients with “difficult asthma” [22]. More precisely, International ERS/ATS Guidelines suggest that in adults with

severe asthma, treatment should be guided by clinical criteria and sputum eosinophil counts in centers experienced in using this technique rather than by clinical criteria alone [14].

In Viet Nam, hardly no clinical setting has applied sputum eosinophil in monitoring asthma because of strict requirements of the method. Thus, here is really avoid space for Vietnamese researchers, especially pulmonologists, that they need to compensate it in the future.

## CONCLUSION

Sputum eosinophil, being a marker of airway inflammation, can serve as a tool for assessing severity

## CONFLIT OF INTEREST

The authors declare no conflict of interest.

## REFERENCES

- Jantina CG et al. Management of the patient with eosinophilic asthma: a new era begins. *ERJ Open Res.* 2015 May; 1(1): 00024-2015.
- Palomino ALM et al. Induced sputum in children and adolescents with asthma: safety, clinical applicability and inflammatory cells aspects in stable patients and during exacerbation. *J. Pediatr. (Rio J.)*, 2005;81:3.
- Vizmanos LG et al. Induced sputum cell count and cytokine profile in atopic and nonatopic children with asthma. *Pediatr Pulmonol.* 2013;48(11):1062-9.
- Hanneke CH, Elisabeth HB. Improving the diagnosis of eosinophilic asthma, *Expert review of Respiratory Medicine*, 2016; 10(10):1093-1103.
- Covar RA et al. Safety and application of induced sputum analysis in childhood asthma, *J Allergy Clin Immunol*, 2004;114(3): 575-582.
- Kansal P et al. Correlation of induced sputum eosinophil levels with clinical parameters in mild and moderate persistent asthma in children aged 7-18 years, *J Asthma*. 2017.1338725.
- Lee YJ et al (2013), Clinical characteristics of eosinophilic and noneosinophilic asthma in children, *Acta Paediatr.*,2013;102(1):53-7.
- Simpson JL et al. Inflammatory subtypes in asthma: assessment and identification using induced sputum, *Respirology*. 2006,11:54e61.
- Green RH et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids, *Thorax*. 2002,57:875e879.
- Baines KJ et al. Transcriptional phenotypes of asthma defined by gene expression profiling of induced sputum samples, *J Allergy Clin Immunol*. 2011;127:153e160. e151ee159.
- Merritt LF, Sally EW. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: The next steps toward personalized care, *J Allergy Clin Immunol*, 2015;135:2.
- Desai M, Oppenheimer J. Elucidating asthma phenotypes and endotypes: progress toward personalized medicine, *Ann Allergy Asthma Immunol* 2016;116:394e401.
- Wenzel SE et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics, *Am J Respir Crit Care Med*. 1999,160(3):1001-1008.
- Veen JCCM et al. Repeatability of cellular and soluble markers of inflammation in induced sputum from patients with asthma, *Eur Respir J*. 1996;9(12):2441-2447.
- Grant LR et al. Procedure for Collection of Induced Sputum Specimen from Children, *Clin Infect Dis* 2012; 54 (suppl\_2): S140-S145.
- Korevaar DA et al. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis, *Lancet Respir Med* 2015; 3: 290-300.
- Hastie AT et al. Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects, *J Allergy Clin Immunol*. 2013;132(1):72-80.
- Berry A, Busse WW. Biomarkers in asthmatic patients: has their time come to direct treatment?, *J Allergy Clin Immunol*. 2016;137(5):1317-1324.
- Zedan MM et al. Airway Inflammatory Biomarker: Could It Tailor the Right Medications for the Right Asthmatic Patient?, *Iran. J. Immunol.* 2016;13:2.

20. Reddel HK, Levy ML. Global Initiative for Asthma Scientific Committee and Dissemination and Implementation Committee. The GINA asthma strategy report: what's new for primary care? *NPJ Prim Care Respir Med.* 2015;25:15050.
21. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma, *Thorax.* 2008; 63: iv1-12.
22. Chung KF et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma, *Eur Respir J.* 2014; 43:343-73.
23. Ioana Maticuta. Is there an ideal biomarker for pediatric asthma?, *International Journal of Recent Scientific Research,* 2015;6(8):5561-5568.